Tirzepatide ���子背景与靶点 — Questions and Answers

By Editorial Desk · published 2025-09-06 · last reviewed 2025-10-02 · Topic

GLP-1 receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-10-02. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tirzepatide 分子背景与靶点

该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Background and Dual Receptor Pharmacology

Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.

Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.

Tirzepatide at a glance

Dual Incretin Receptor Agonism

In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.

Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

Related pages on this site

• Durable playbook
• Focused overview
• Verified notes
• Professional archive
• Material overview
• Modular dataset
• Optimized update
• Sustainable workbook

Background And Receptor Mechanism

Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.

Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.

Reference notes

Assuming that atmospheric circulation and elevation has not changed significantly over the poles, the temperature of ice formation can be calculated as equilibrium fractionation between phases of water that is known for different temperatures. Water molecules are also subject to Rayleigh fractionation as atmospheric water moves from the equator poleward which results in progressive depletion of 18O, or lower δ18O values. The δ18O ratio can also be used in paleothermometry for certain types of fossils. The fossil material used is generally calcite or aragonite, however oxygen isotope paleothermometry has also been done of phosphatic fossils using SHRIMP. For determination of ocean temperatures over geologic time, multiple fossils of the same species in different stratigraphic layers would be measured, and the difference between them would indicate long term changes. 18O has also been used to trace ocean composition and temperature which seafood is from. In the study of plants' photorespiration, the labeling of atmosphere by oxygen-18 allows for the measurement of oxygen uptake by the photorespiration pathway. Labeling by 18O2 gives the unidirectional flux of O2 uptake, while there is a net photosynthetic 16O2 evolution. It was demonstrated that, under preindustrial atmosphere, most plants reabsorb, by photorespiration, half of the oxygen produced by photosynthesis. Then, the yield of photosynthesis was halved by the presence of oxygen in atmosphere.

== External links == HFE+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: Q30201 (Hereditary hemochromatosis protein) at the PDBe-KB.

== Original == The intricate imagery on the lorica musculata (typical of legates) refers to the Parthian Empire’s restitution of Roman eagle insignia, which had previously been captured from Marcus Licinius Crassus, to Augustus in 20 BC, one of his most significant diplomatic accomplishments. The date of the (hypothetical) bronze original is therefore later than 20 BC. The event detailed on the armor symbolizes the Pax Romana initiated by Rome’s first Emperor. The fact that Augustus is depicted barefooted is intended to be a divine representation, as this was a standard depiction of gods or heroes in classical iconography. The date of the marble copy would presumably fall between that date and Livia's death in AD 29. The statue might have been commissioned by Tiberius, the successor to Augustus, possibly as a gift to his mother Livia (since it was found in her Villa ad Gallinas Albas in the vicinity of the ninth mile-marker of the Via Flaminia, and close to a late imperial gate and aqueduct called Prima Porta) after Augustus' death and in honor of the woman who had campaigned for so long for him to become the next Caesar. This hypothesis is based on the fact that the central reliefs on the heroic cuirass depict the retrieval of Crassus' standards captured by the Parthians, an event in which the young Tiberius himself served as an intermediary with the Parthian king, and which was possibly his greatest service to his adoptive father Augustus.

Arashiro Toshiaki, Ryukyu-Okinawa Rekishi Jinbutsuden, Okinawajijishuppan, 2006 p66 ISBN 978-4-903042-04-6 "Reevaluation of surgical achievements by Tokumei Takamine". Matsuki A. Masui. November 2000; 49(11):1285-9. Japanese. "The secret anesthetic used in the repair of a hare-lip performed by Tokumei Takamine in Ryukyu". Matsuki A. Nippon Ishigaku Zasshi. October 1985 31(4):463-89. Japanese.

Sources: en.wikipedia.org

Notes from published material

In the English language, medical terms generally have a regular morphology, often being compound words that comprise three kinds of morphemes: roots, prefixes, and suffixes. The etymology of medical terms often originates from Latin (particularly Neo-Latin) and Ancient Greek, with such medical terms being examples of neoclassical compounds. Each language may supply relevant morphemes for medical terms. For example, there are two primary roots for medical terminology relating to kidneys – one from Greek (νεφρός nephr(os)) and one from Latin (ren(es)). Lexical items of medical terminology, which forms part of international scientific vocabulary (ISV), are translingual (that is, being used across multiple languages). The use of ISV was a driving force in the development of the constructed language known as Interlingua. From the 1950s to late 1970s, a number of medical journals were published, or used, Interlingua.

=== Measurement methods === Reported averages vary partly because penile size is affected by erection state, measurement technique and whether the measurement is self-reported or taken by a clinician. In clinical studies, length is commonly measured along the dorsal side from the pubic bone to the tip of the glans, with the pre-pubic fat pad compressed to the bone. Circumference is usually measured at the base or mid-shaft. Stretched flaccid length is also used in clinical assessment, although it is not identical to erect length in all men and can be affected by the amount of traction applied during measurement.

== Prognosis == Gynecomastia itself is a benign finding. It does not confer a poor prognosis; for some patients with underlying pathologies such as testicular cancer, the prognosis may be worse. The glandular tissue typically grows under the influence of hormonal stimulation and is often tender or painful. Furthermore, gynecomastia frequently presents social and psychological difficulties such as low self-esteem, depression, or shame.

==== Treatment ==== Treatment should resolve reversible pulpitis; early treating may help prevent irreversible pulpitis Follow-up required to determine whether the reversible pulpitis has returned to a normal status

=== Other activities === High has been on NIH study sections for hematology and for therapeutic approaches to genetic disease. She was on the National Heart, Lung and Blood Advisory Council, on the NIH Clinical Center Advisory Council, and on the Board of Scientific Counsellors for the National Eye Institute. She did a four year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapy (2001–2005) and was the President of the American Society of Gene and Cell Therapy (2004–2005).

Sources: en.wikipedia.org

Frequently asked questions